All Stories

Fierce Pharma Asia—China troubles at Merck, AZ; Astellas' C-suite shuffle and Izervay stumbles

Merck & Co. and AstraZeneca suffered notable losses in China during the fourth quarter. Astellas shuffled its C-suite and revealed a slowdown for its newly launched eye disease med Izervay. Plus more.

Feb 9, 2025 - 21:43
 0
Fierce Pharma Asia—China troubles at Merck, AZ; Astellas' C-suite shuffle and Izervay stumbles
Merck & Co. and AstraZeneca suffered notable losses in China during the fourth quarter. Astellas shuffled its C-suite and revealed a slowdown for its newly launched eye disease med Izervay. Plus more.
Read More

Tags:

Previous Article

Looking ahead at the most anticipated drug launches of 2025

Next Article

Regeneron tangles with Sanofi over commercial transparency in long-running Dupix...

Related Posts

Argenx banks on key prefilled syringe approval for Vyvgart to help drive profitability in 2025: exec

Argenx banks on key prefilled syringe approval for Vyvg...

Feb 19, 2025  0

Regulatory tracker: Gilead's seladelpar nabs EU approval in primary biliary cholangitis

Regulatory tracker: Gilead's seladelpar nabs EU approva...

Feb 21, 2025  0

Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch

Gilead, riding high from HIV sales boost, charts course...

Feb 12, 2025  0